Internship

Quality Intern

Confirmed live in the last 24 hours

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

No salary listed

Fishers, IN, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
SAP Products
Requirements
  • Completing Undergraduate Degree/Pharmacy Program
  • Majoring in STEM preferred (e.g., Pharmacy, Chemistry, Statistics, etc)
  • Knowledgeable in Microsoft tools (PP, XL, Visio, etc)
  • Experiences utilizing other COTS (Commercial Of-The-Shelf) IT tools (e.g., SAP, Data Management, Databases, etc.)
  • Strong verbal and written communication skills
  • Ability to meet tight timelines
  • Agility with fast moving, changing deliverables
Responsibilities
  • Develop clear understanding of Document Management structures in Master Control
  • Coordinate and organize documents needing to be uploaded/approved in Master Control with key business partners in Manufacturing, Logistics/Supply Chain, and Regulatory
  • Interface with Master Control SME to update/provide improvement updates to Master Control
  • Partner with Commercial QA SME to validate/audit document management updates
  • Report weekly progress to Commercial QA Leader and make adjustments as needed
  • Leverage Master Control tools and identify efficiency opportunities
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells biopharmaceutical products aimed at improving the diagnosis and treatment of cancer and rare diseases. The company focuses on creating therapeutic and diagnostic solutions that use targeted radiation, which helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. Their product pipeline includes treatments for urologic cancers like prostate and kidney cancer, neuro-oncology conditions such as glioma, musculoskeletal cancers like sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. The company emphasizes sustainability, patient care, and ethical practices, aiming to create lasting value for patients, shareholders, and employees.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's priority review for TLX250-CDx indicates strong potential in kidney cancer imaging.
  • Promising IPAX-Linz study results for TLX101 could boost market share in neuro-oncology.
  • Acquisition of ImaginAb's platform allows exploration of new disease areas with radiotherapeutics.

What critics are saying

  • Increased competition from Novartis and Bayer may impact Telix's market share.
  • Supply shortages of isotopes like gallium-68 could affect product availability in Europe.
  • Regulatory hurdles in Asia may delay Telix's expansion into new markets.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and ethical practices into its operations and patient care.
  • Telix has a robust global supply chain ensuring product availability worldwide.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
PR Newswire
Apr 15th, 2025
Ipax-Linz Study Reports Promising Efficacy For Tlx101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2]. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma. Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]

Siam News Network
Apr 6th, 2025
Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.

Telix Pharmaceuticals
Apr 3rd, 2025
Anne Whitaker Appointed as Non-Executive Director

Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025[1].

Pipeline Review
Apr 2nd, 2025
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Telix holds the exclusive worldwide rights to develop and commercialize radiolabelled forms of olaratumab, which was originally developed by Eli Lilly and Company (Lilly).

Telix Pharmaceuticals
Mar 19th, 2025
EAU25: Telix presents at Europe's largest urological event

Join Telix this week at the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain.